Clinical Trials Logo

Filter by:
NCT ID: NCT04839510 Recruiting - Clinical trials for Metastatic Urothelial Carcinoma

A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Start date: April 20, 2021
Phase: Phase 2
Study type: Interventional

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 as single agent in patients with HER2-positive unresectable locally advanced or metastatic urothelium cancer.

NCT ID: NCT04839341 Recruiting - Clinical trials for Relapsed/Refractory AML

Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients

Start date: February 24, 2021
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and tolerability of uproleselan(GMI-1271), a specific E-selectin antagonist, and characterize the pharmacokinetic (PK) profile of uproleselan, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients.

NCT ID: NCT04839055 Recruiting - Clinical trials for Castration-resistant Prostate Cancer

The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC

CoA-CRPC
Start date: March 18, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to compare the therapy effects and clinical safety of a regulatory metabolic compound, coenzyme A (CoA) with a marketed drug, abiraterone, in Chinese patients with castration-resistant prostate cancer (CRPC) .

NCT ID: NCT04838964 Recruiting - Clinical trials for Advanced or Metastatic Biliary Tract Cancer

A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Start date: April 28, 2021
Phase: Phase 2
Study type: Interventional

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 as single agent in EGFR-positive unresectable locally advanced or metastatic biliary tract cancer patients who have progressed during or relapsed after at least one prior standard therapy.

NCT ID: NCT04838704 Recruiting - Clinical trials for Graft Versus Host Disease

Ruxolitinib With Calcineurin and Methotrexate vs. Calcineurin Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation

Start date: April 8, 2021
Phase: Phase 4
Study type: Interventional

Low Dose Ruxolitinib with Calcineurin and Methotrexate vs. Calcineurin plus Methotrexate and Mycophenolate mofetil as Graft Versus Host Disease prophylaxis for HLA-haploidentical hematopoietic stem cell transplantation in low-dose antithymocyte globulin (ATG) system.

NCT ID: NCT04838548 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer

Start date: September 4, 2020
Phase: Phase 2
Study type: Interventional

The objective of this study is to assess the efficacy, safety of MRG003 as single agent in EGFR-positive advanced non-small cell lung cancer

NCT ID: NCT04838535 Recruiting - Clinical trials for Polycystic Ovary Syndrome

Follicular Fluid Raman Shifts and IVF Outcomes

Start date: June 19, 2019
Phase: N/A
Study type: Interventional

This study intends to collect about 150 cases of follicular fluid samples from PCOS and non-PCOS infertility patients undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycles (in clinical routines).We tend to detect Raman metabolic profile of the follicular fluid of the PCOS and non-PCOS groups, and find the correlation between the metabolic profile of the follicular fluid of PCOS patients and the oocyte quality, IVF outcome and subsequent embryo development are also under investigation. Metabolomics analysis was applied to look for markers of follicular fluid in PCOS patients, and further exploring data and strategies to improve the embryonic development potential and IVF outcome of PCOS patients.

NCT ID: NCT04838132 Recruiting - Clinical trials for Coronary Artery Bypass Grafting or Heart Valve Surgery Via Median Sternotomy

Transversus Thoracis Muscle Plane Block Plus Rectus Sheath Block in the Perioperative Pain Management of Cardiac Surgery

Start date: March 16, 2021
Phase: N/A
Study type: Interventional

An emerging regional block technique, transverse thoracic muscle block covers the T2-T6 intercostal nerves and can effectively relieve perioperative pain during median sternotomy. Bilateral transverse thoracic muscle plane( TTP) block is expected to be a new analgesic mode in perioperative of cardiac surgery via sternotomy.

NCT ID: NCT04837625 Recruiting - Myasthenia Gravis Clinical Trials

Study of Myasthenic Crisis in China

Start date: October 1, 2020
Phase:
Study type: Observational

This study is a multicenter, prospective, observational research. It will register the basic demographic information, medical history characteristics, clinical features, auxiliary examinations, treatment, outcomes of tracheal intubation/ventilator related events, and clinical outcomes of Myasthenic Crisis patients. The objectives including: 1. Obtain epidemiological data of MC in China; 2. Establish a standardized registration system for MC patients in China; 3. Explore the epidemiology, clinical characteristics, serological characteristics, clinical characteristics of MC, predisposing and predictive factors, extubation process/time, weaning/extubation outcome and predictors of clinical outcome in Chinese MC patients.

NCT ID: NCT04837612 Recruiting - Clinical trials for DCM - Dilated Cardiomyopathy

Observational Study for Patients With Dilated Cardiomyopathy

Start date: January 1, 2019
Phase:
Study type: Observational

Observational study on patients with dilated cardiomyopathy aims to investigate the correlation between cardiac fibrosis, as indicated by cardiac magnetic resonance, and the prognosis of patients with dilated cardiomyopathy, and further to explore biomarkers for cardiac fibrosis and adverse prognosis of dilated cardiomyopathy. Therefore, endpoints indluding all-cause mortality, cardiovascular death, ventricular arrythmia, non-fatal stroke, non-fatal myocardial infarction, sudden death, successful cardiopulmonary resuscitation will be evaluated.